The estimated Net Worth of Michael Schmertzler is at least $4.43 Milion dollars as of 8 January 2024. Mr. Schmertzler owns over 1,500 units of PTC Therapeutics Inc stock worth over $3,719,634 and over the last 20 years he sold PTCT stock worth over $86,575. In addition, he makes $628,710 as Independent Chairman of the Board at PTC Therapeutics Inc.
Michael has made over 7 trades of the PTC Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 1,500 units of PTCT stock worth $41,715 on 8 January 2024.
The largest trade he's ever made was buying 533,333 units of PTC Therapeutics Inc stock on 29 January 2013 worth over $7,999,995. On average, Michael trades about 15,110 units every 87 days since 2004. As of 8 January 2024 he still owns at least 115,266 units of PTC Therapeutics Inc stock.
You can see the complete history of Mr. Schmertzler stock trades at the bottom of the page.
Michael Schmertzler serves as Independent Chairman of the Board of the Company. Mr. Schmertzler served as a Managing Director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P., a private equity fund, and the Chair of the investment committee of Credit Suisse First Boston Equity Partners, L.P. From 1997 to 2001, Mr. Schmertzler was Co-Head of United States and Canadian Private Equity at Credit Suisse First Boston, an investment banking firm. Prior to 1997, Mr. Schmertzler held various management positions with Morgan Stanley and its affiliates, including President of Morgan Stanley Leveraged Capital Funds and head of Morgan Stanley's biotechnology pharmaceuticals group, and was Managing Director and Chief Financial Officer of Lehman Brothers Kuhn Loeb and Head of International Sales and Trading and Investment Banking at its successor, Lehman Brothers, both investment banking firms. Mr. Schmertzler is currently a director of Lehman Commercial Paper Incorporated, a liquidating post-bankruptcy subsidiary of Lehman Brothers Holdings, Incorporated. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer at Yale University and also is a visiting professor at Yale-NUS. Mr. Schmertzler received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History and City Planning and an M.B.A. from the Harvard Business School.
As the Independent Chairman of the Board of PTC Therapeutics Inc, the total compensation of Michael Schmertzler at PTC Therapeutics Inc is $628,710. There are 8 executives at PTC Therapeutics Inc getting paid more, with Stuart Peltz having the highest compensation of $7,759,440.
Michael Schmertzler is 68, he's been the Independent Chairman of the Board of PTC Therapeutics Inc since 2004. There are 4 older and 15 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
Michael's mailing address filed with the SEC is 2270 PINELLAS POINT DRIVE SOUTH, , ST. PETERSBURG, FL, 33712.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel oraz Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: